VistaGen Therapeutics(VTGN) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Vistagen Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)—August 13, 2024-- Vistagen(Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neuro ...